login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Similar results for laser ablation and surgery at two years


Tuesday, 11 Aug 2009 15:10
Lars Rasmussen
Lars Rasmussen


A study conducted in Denmark has suggested that medium term efficacy and safety of endovascular laser ablation and stripping of the great saphenous veins present similar results. Lars Rasmussen, Danish Vein Centres and Surgical Clinic Roskilde, presented the two-year data at the European Venous Forum.


The objective of the study was to compare laser ablation with stripping (HL/S) with regards to safety and efficacy, quality of life and economy. The inclusion criteria was age 18–80 years, informed consent, varicose veins and great saphenous veins incompetence as defined by duplex, CEAP clinical classification C2–3, previous high ligation and local treatment accepted if great saphenous vein was preserved in its entire length from groin to knee. Bilateral treatment was permitted, provided both limbs were receiving the same treatment during the same operation.


Patients (121) with great saphenous vein insufficiency were randomised using sealed envelopes. Diagnostic was performed with duplex scan. The treatment consisted of high ligation and pin stripping (n=59, 68 legs) or endovascular laser 980 nm, Biolitec (n=62, 69 legs). Division of all saphenous tributaries was done beyond their secondary branches. The procedure included tumescent local anaesthesia, with lidocaine and adrenaline, 0.1%, and compression and absorbant bandage 48 hours, grade 1 stockings for two weeks. Follow-up was conducted at two weeks, four weeks, three, six, 12, and months for safety, efficacy, pain score (1–10 days), time off work and normal activity, economy, VCSS, AVVSS, SF-36 (quality of life), recurrence rate and -pattern. Follow-up at 36 months is also planned.


Two HL/S procedures failed while three great saphenous veins recanalised in the endovascular laser ablation group. The groups experienced similar improvement in quality of life scores and VCSS score. Complications were rare and minor. Postoperative morbidity, improvements in quality of life, venous clinical severity score and costs were similar in the two groups. Twenty-three (33%) and 18 (26%) of the stripping and endovascular laser ablation group respectively developed new varicose veins, a non-significant difference. The distribution of the recurrent varicose veins was not different between the groups; new incompetent femoral perforations being the most frequent finding at follow-up. A total of 11% were re-operated within two years.


The study concluded that expect for slightly increased postoperative pain and bruising in the HL/S group, no differences were found between the two treatment modalities. The treatments were equally safe and efficient in eliminating great saphenous veins reflux, alleviate symptons and signs of varicosities and improve quality of life. The recurrence rate was disappointingly high in both groups, as seen in other studies. Longer term outcomes, particularly with respect to recurrence rates must be investigated in future studies.




Add New Comment

Most popular


ROADSTER trial studying new path to carotid revascularisation completes patient enrolment
Friday, 18 Jul 2014
The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally ... ROADSTER trial studying new path to carotid revascularisation completes patient enrolment

Endovascular-first strategy for aortoiliac lesions irrespectively of TASC category
Thursday, 17 Jul 2014
Two-year data from a prospective, multicentre study suggest that endovascular therapy with stenting may be considered the preferred first-line treatment option for aortoiliac lesions, irrespectively ... Endovascular-first strategy for aortoiliac lesions irrespectively of TASC category

Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak
Wednesday, 13 Aug 2014
Elective open surgical conversion for type Ia endoleak after endovascular aneurysm repair (EVAR) is not associated with increased morbidity or mortality compared with open juxtarenal aneurysm repair ... Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak

Features


SPECT can predict cardiovascular mortality in elective aneurysm repair patients
Wednesday, 12 Mar 2014
Kimihiro Komori and Yosuke Inoue analyse the results of a study that concluded that preoperative pharmacologic stress myocardial perfusion SPECT is not only safe, but is also a useful method to ... SPECT can predict cardiovascular mortality in elective aneurysm repair patients

Hybrid techniques for the arch: are they effective and durable?
Monday, 17 Feb 2014
Piergiorgio Cao writes that despite the perioperative mortality risk, the late outcome of endovascular arch repair presents a low rate of aorta-related deaths and reinterventions and acceptable mid-... Hybrid techniques for the arch: are they effective and durable?

Profiles


Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Andrew Holden
Tuesday, 11 Feb 2014
Andrew Holden has been involved in the investigation of several endovascular devices for the ... Andrew Holden

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions